| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,
Envivo is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.
United Vein Centers is Tampas choice for vein care. We have extensive experience treating both varicose & spider veins - particularly our physician, Dr. Wazni.